Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors Eric P. SiposBetty TylerH. Brem ORIGINAL ARTICLE Pages: 383 - 389
Antiestrogenic activity of DP-TAT-59, an active metabolite of TAT-59 against human breast cancer T. TokoJiro ShibataYuji Yamada ORIGINAL ARTICLE Pages: 390 - 398
Potentiation of etoposide-induced apoptosis by staurosporine in human tumor cells is associated with events downstream of DNA-protein complex formation Richard B. LockBruce S. ThompsonLolita Stribinskiene ORIGINAL ARTICLE Pages: 399 - 409
Preclinical trial of doxorubicin entrapped in sterically stabilized liposomes in dogs with spontaneously arising malignant tumors D. M. VailLaura D. KravisE. Gregory MacEwen ORIGINAL PAPER Pages: 410 - 416
Induction of apoptosis in multi-drug resistant (MDR) human glioblastoma cells by SN-38, a metabolite of the camptothecin derivative CPT-11 Shouji NakatsuS. KondoGene H. Barnett ORIGINAL ARTICLE Pages: 417 - 423
The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide]to circumvent three multidrug-resistance phenotypes in vitro R. A. DaveyGloria M. SuMary W. Davey ORIGINAL ARTICLE Pages: 424 - 430
Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy V. KurowskiT. Wagner ORIGINAL ARTICLE Pages: 431 - 439
Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital E. GuptaXiaolin WangM. J. Ratain ORIGINAL ARTICLE Pages: 440 - 444
Ras oncogene-transformed and nontransformed cell populations are each heterogeneous but respond differently to the chemotherapeutic drug cytosine arabinoside (Ara-C) D. E. AxelrodY. GusevJohn W. Gamel ORIGINAL ARTICLE Pages: 445 - 451
Superiority of cyclosporin A over PSC-833 in enhancement of VP-16 efficacy in murine tumors in vivo L. M. SlaterPaula SweetKathyrn Osann ORIGINAL ARTICLE Pages: 452 - 454
DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides P. J. SmithNicola J. BluntLaurence H. Patterson ORIGINAL ARTICLE Pages: 455 - 461
Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and / or hormonal therapy A. A. ShlebakD. B. Smith SHORT COMMUNICATION Pages: 462 - 466
Differential toxicity of camptothecin, topotecan and 9-aminocamptothecin to human, canine, and murine myeloid progenitors (CFU-GM) in vitro C. L. Erickson-MillerRichard D. MayRalph E. Parchment SHORT COMMUNICATION Pages: 467 - 472
